Global Disease-Modifying Antirheumatic Drug Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Disease-Modifying Antirheumatic Drug Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Disease-Modifying Antirheumatic Drug by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Disease-Modifying Antirheumatic Drug by Country/Region, 2017, 2022 & 2028

2.2 Disease-Modifying Antirheumatic Drug Segment by Type

2.2.1 Non-Steroidal Anti-Inflammatory Drugs

2.2.2 Steroidal Anti-Inflammatory Drugs

2.2.3 Slow Acting Drug

2.2.4 Immunological Preparation

2.3 Disease-Modifying Antirheumatic Drug Sales by Type

2.3.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2022)

2.3.2 Global Disease-Modifying Antirheumatic Drug Revenue and Market Share by Type (2017-2022)

2.3.3 Global Disease-Modifying Antirheumatic Drug Sale Price by Type (2017-2022)

2.4 Disease-Modifying Antirheumatic Drug Segment by Application

2.4.1 Pharmaceutical Industry

2.4.2 Hospital and Clinic

2.4.3 Other

2.5 Disease-Modifying Antirheumatic Drug Sales by Application

2.5.1 Global Disease-Modifying Antirheumatic Drug Sale Market Share by Application (2017-2022)

2.5.2 Global Disease-Modifying Antirheumatic Drug Revenue and Market Share by Application (2017-2022)

2.5.3 Global Disease-Modifying Antirheumatic Drug Sale Price by Application (2017-2022)

3 Global Disease-Modifying Antirheumatic Drug by Company

3.1 Global Disease-Modifying Antirheumatic Drug Breakdown Data by Company

3.1.1 Global Disease-Modifying Antirheumatic Drug Annual Sales by Company (2020-2022)

3.1.2 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2020-2022)

3.2 Global Disease-Modifying Antirheumatic Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Disease-Modifying Antirheumatic Drug Revenue by Company (2020-2022)

3.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Company (2020-2022)

3.3 Global Disease-Modifying Antirheumatic Drug Sale Price by Company

3.4 Key Manufacturers Disease-Modifying Antirheumatic Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Disease-Modifying Antirheumatic Drug Product Location Distribution

3.4.2 Players Disease-Modifying Antirheumatic Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Disease-Modifying Antirheumatic Drug by Geographic Region

4.1 World Historic Disease-Modifying Antirheumatic Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Disease-Modifying Antirheumatic Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Disease-Modifying Antirheumatic Drug Annual Revenue by Geographic Region

4.2 World Historic Disease-Modifying Antirheumatic Drug Market Size by Country/Region (2017-2022)

4.2.1 Global Disease-Modifying Antirheumatic Drug Annual Sales by Country/Region (2017-2022)

4.2.2 Global Disease-Modifying Antirheumatic Drug Annual Revenue by Country/Region

4.3 Americas Disease-Modifying Antirheumatic Drug Sales Growth

4.4 APAC Disease-Modifying Antirheumatic Drug Sales Growth

4.5 Europe Disease-Modifying Antirheumatic Drug Sales Growth

4.6 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Growth

5 Americas

5.1 Americas Disease-Modifying Antirheumatic Drug Sales by Country

5.1.1 Americas Disease-Modifying Antirheumatic Drug Sales by Country (2017-2022)

5.1.2 Americas Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2022)

5.2 Americas Disease-Modifying Antirheumatic Drug Sales by Type

5.3 Americas Disease-Modifying Antirheumatic Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Disease-Modifying Antirheumatic Drug Sales by Region

6.1.1 APAC Disease-Modifying Antirheumatic Drug Sales by Region (2017-2022)

6.1.2 APAC Disease-Modifying Antirheumatic Drug Revenue by Region (2017-2022)

6.2 APAC Disease-Modifying Antirheumatic Drug Sales by Type

6.3 APAC Disease-Modifying Antirheumatic Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Disease-Modifying Antirheumatic Drug by Country

7.1.1 Europe Disease-Modifying Antirheumatic Drug Sales by Country (2017-2022)

7.1.2 Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2022)

7.2 Europe Disease-Modifying Antirheumatic Drug Sales by Type

7.3 Europe Disease-Modifying Antirheumatic Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Disease-Modifying Antirheumatic Drug by Country

8.1.1 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Country (2017-2022)

8.1.2 Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2022)

8.2 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Type

8.3 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Disease-Modifying Antirheumatic Drug

10.3 Manufacturing Process Analysis of Disease-Modifying Antirheumatic Drug

10.4 Industry Chain Structure of Disease-Modifying Antirheumatic Drug

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Disease-Modifying Antirheumatic Drug Distributors

11.3 Disease-Modifying Antirheumatic Drug Customer

12 World Forecast Review for Disease-Modifying Antirheumatic Drug by Geographic Region

12.1 Global Disease-Modifying Antirheumatic Drug Market Size Forecast by Region

12.1.1 Global Disease-Modifying Antirheumatic Drug Forecast by Region (2023-2028)

12.1.2 Global Disease-Modifying Antirheumatic Drug Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Disease-Modifying Antirheumatic Drug Forecast by Type

12.7 Global Disease-Modifying Antirheumatic Drug Forecast by Application

13 Key Players Analysis

13.1 AbbVie

13.1.1 AbbVie Company Information

13.1.2 AbbVie Disease-Modifying Antirheumatic Drug Product Offered

13.1.3 AbbVie Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 AbbVie Main Business Overview

13.1.5 AbbVie Latest Developments

13.2 Amgen

13.2.1 Amgen Company Information

13.2.2 Amgen Disease-Modifying Antirheumatic Drug Product Offered

13.2.3 Amgen Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Amgen Main Business Overview

13.2.5 Amgen Latest Developments

13.3 Pfizer

13.3.1 Pfizer Company Information

13.3.2 Pfizer Disease-Modifying Antirheumatic Drug Product Offered

13.3.3 Pfizer Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Pfizer Main Business Overview

13.3.5 Pfizer Latest Developments

13.4 Roche Holding AG

13.4.1 Roche Holding AG Company Information

13.4.2 Roche Holding AG Disease-Modifying Antirheumatic Drug Product Offered

13.4.3 Roche Holding AG Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Roche Holding AG Main Business Overview

13.4.5 Roche Holding AG Latest Developments

13.5 Novartis International AG

13.5.1 Novartis International AG Company Information

13.5.2 Novartis International AG Disease-Modifying Antirheumatic Drug Product Offered

13.5.3 Novartis International AG Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Novartis International AG Main Business Overview

13.5.5 Novartis International AG Latest Developments

13.6 Johnson & Johnson

13.6.1 Johnson & Johnson Company Information

13.6.2 Johnson & Johnson Disease-Modifying Antirheumatic Drug Product Offered

13.6.3 Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Johnson & Johnson Main Business Overview

13.6.5 Johnson & Johnson Latest Developments

13.7 Bristol-Myers Squibb

13.7.1 Bristol-Myers Squibb Company Information

13.7.2 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product Offered

13.7.3 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Bristol-Myers Squibb Main Business Overview

13.7.5 Bristol-Myers Squibb Latest Developments

13.8 Merck

13.8.1 Merck Company Information

13.8.2 Merck Disease-Modifying Antirheumatic Drug Product Offered

13.8.3 Merck Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Merck Main Business Overview

13.8.5 Merck Latest Developments

13.9 UCB S.A.

13.9.1 UCB S.A. Company Information

13.9.2 UCB S.A. Disease-Modifying Antirheumatic Drug Product Offered

13.9.3 UCB S.A. Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 UCB S.A. Main Business Overview

13.9.5 UCB S.A. Latest Developments

13.10 Eli Lilly and Company

13.10.1 Eli Lilly and Company Company Information

13.10.2 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product Offered

13.10.3 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Eli Lilly and Company Main Business Overview

13.10.5 Eli Lilly and Company Latest Developments

14 Research Findings and Conclusion

Table 1. Disease-Modifying Antirheumatic Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Disease-Modifying Antirheumatic Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Non-Steroidal Anti-Inflammatory Drugs

Table 4. Major Players of Steroidal Anti-Inflammatory Drugs

Table 5. Major Players of Slow Acting Drug

Table 6. Major Players of Immunological Preparation

Table 7. Global Disease-Modifying Antirheumatic Drug Sales by Type (2017-2022) & (MT)

Table 8. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2022)

Table 9. Global Disease-Modifying Antirheumatic Drug Revenue by Type (2017-2022) & ($ million)

Table 10. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2017-2022)

Table 11. Global Disease-Modifying Antirheumatic Drug Sale Price by Type (2017-2022) & (USD/MT)

Table 12. Global Disease-Modifying Antirheumatic Drug Sales by Application (2017-2022) & (MT)

Table 13. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2022)

Table 14. Global Disease-Modifying Antirheumatic Drug Revenue by Application (2017-2022)

Table 15. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2017-2022)

Table 16. Global Disease-Modifying Antirheumatic Drug Sale Price by Application (2017-2022) & (USD/MT)

Table 17. Global Disease-Modifying Antirheumatic Drug Sales by Company (2020-2022) & (MT)

Table 18. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2020-2022)

Table 19. Global Disease-Modifying Antirheumatic Drug Revenue by Company (2020-2022) ($ Millions)

Table 20. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Company (2020-2022)

Table 21. Global Disease-Modifying Antirheumatic Drug Sale Price by Company (2020-2022) & (USD/MT)

Table 22. Key Manufacturers Disease-Modifying Antirheumatic Drug Producing Area Distribution and Sales Area

Table 23. Players Disease-Modifying Antirheumatic Drug Products Offered

Table 24. Disease-Modifying Antirheumatic Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global Disease-Modifying Antirheumatic Drug Sales by Geographic Region (2017-2022) & (MT)

Table 28. Global Disease-Modifying Antirheumatic Drug Sales Market Share Geographic Region (2017-2022)

Table 29. Global Disease-Modifying Antirheumatic Drug Revenue by Geographic Region (2017-2022) & ($ millions)

Table 30. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Geographic Region (2017-2022)

Table 31. Global Disease-Modifying Antirheumatic Drug Sales by Country/Region (2017-2022) & (MT)

Table 32. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Country/Region (2017-2022)

Table 33. Global Disease-Modifying Antirheumatic Drug Revenue by Country/Region (2017-2022) & ($ millions)

Table 34. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Country/Region (2017-2022)

Table 35. Americas Disease-Modifying Antirheumatic Drug Sales by Country (2017-2022) & (MT)

Table 36. Americas Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2017-2022)

Table 37. Americas Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2022) & ($ Millions)

Table 38. Americas Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2017-2022)

Table 39. Americas Disease-Modifying Antirheumatic Drug Sales by Type (2017-2022) & (MT)

Table 40. Americas Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2022)

Table 41. Americas Disease-Modifying Antirheumatic Drug Sales by Application (2017-2022) & (MT)

Table 42. Americas Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2022)

Table 43. APAC Disease-Modifying Antirheumatic Drug Sales by Region (2017-2022) & (MT)

Table 44. APAC Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2017-2022)

Table 45. APAC Disease-Modifying Antirheumatic Drug Revenue by Region (2017-2022) & ($ Millions)

Table 46. APAC Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2017-2022)

Table 47. APAC Disease-Modifying Antirheumatic Drug Sales by Type (2017-2022) & (MT)

Table 48. APAC Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2022)

Table 49. APAC Disease-Modifying Antirheumatic Drug Sales by Application (2017-2022) & (MT)

Table 50. APAC Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2022)

Table 51. Europe Disease-Modifying Antirheumatic Drug Sales by Country (2017-2022) & (MT)

Table 52. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2017-2022)

Table 53. Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2022) & ($ Millions)

Table 54. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2017-2022)

Table 55. Europe Disease-Modifying Antirheumatic Drug Sales by Type (2017-2022) & (MT)

Table 56. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2022)

Table 57. Europe Disease-Modifying Antirheumatic Drug Sales by Application (2017-2022) & (MT)

Table 58. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2022)

Table 59. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Country (2017-2022) & (MT)

Table 60. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2017-2022)

Table 61. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2022) & ($ Millions)

Table 62. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2017-2022)

Table 63. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Type (2017-2022) & (MT)

Table 64. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2022)

Table 65. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Application (2017-2022) & (MT)

Table 66. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2022)

Table 67. Key Market Drivers & Growth Opportunities of Disease-Modifying Antirheumatic Drug

Table 68. Key Market Challenges & Risks of Disease-Modifying Antirheumatic Drug

Table 69. Key Industry Trends of Disease-Modifying Antirheumatic Drug

Table 70. Disease-Modifying Antirheumatic Drug Raw Material

Table 71. Key Suppliers of Raw Materials

Table 72. Disease-Modifying Antirheumatic Drug Distributors List

Table 73. Disease-Modifying Antirheumatic Drug Customer List

Table 74. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Region (2023-2028) & (MT)

Table 75. Global Disease-Modifying Antirheumatic Drug Sales Market Forecast by Region

Table 76. Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 77. Global Disease-Modifying Antirheumatic Drug Revenue Market Share Forecast by Region (2023-2028)

Table 78. Americas Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2023-2028) & (MT)

Table 79. Americas Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 80. APAC Disease-Modifying Antirheumatic Drug Sales Forecast by Region (2023-2028) & (MT)

Table 81. APAC Disease-Modifying Antirheumatic Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 82. Europe Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2023-2028) & (MT)

Table 83. Europe Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 84. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2023-2028) & (MT)

Table 85. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 86. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Type (2023-2028) & (MT)

Table 87. Global Disease-Modifying Antirheumatic Drug Sales Market Share Forecast by Type (2023-2028)

Table 88. Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 89. Global Disease-Modifying Antirheumatic Drug Revenue Market Share Forecast by Type (2023-2028)

Table 90. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Application (2023-2028) & (MT)

Table 91. Global Disease-Modifying Antirheumatic Drug Sales Market Share Forecast by Application (2023-2028)

Table 92. Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 93. Global Disease-Modifying Antirheumatic Drug Revenue Market Share Forecast by Application (2023-2028)

Table 94. AbbVie Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors

Table 95. AbbVie Disease-Modifying Antirheumatic Drug Product Offered

Table 96. AbbVie Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)

Table 97. AbbVie Main Business

Table 98. AbbVie Latest Developments

Table 99. Amgen Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors

Table 100. Amgen Disease-Modifying Antirheumatic Drug Product Offered

Table 101. Amgen Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)

Table 102. Amgen Main Business

Table 103. Amgen Latest Developments

Table 104. Pfizer Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors

Table 105. Pfizer Disease-Modifying Antirheumatic Drug Product Offered

Table 106. Pfizer Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)

Table 107. Pfizer Main Business

Table 108. Pfizer Latest Developments

Table 109. Roche Holding AG Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors

Table 110. Roche Holding AG Disease-Modifying Antirheumatic Drug Product Offered

Table 111. Roche Holding AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)

Table 112. Roche Holding AG Main Business

Table 113. Roche Holding AG Latest Developments

Table 114. Novartis International AG Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors

Table 115. Novartis International AG Disease-Modifying Antirheumatic Drug Product Offered

Table 116. Novartis International AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)

Table 117. Novartis International AG Main Business

Table 118. Novartis International AG Latest Developments

Table 119. Johnson & Johnson Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors

Table 120. Johnson & Johnson Disease-Modifying Antirheumatic Drug Product Offered

Table 121. Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)

Table 122. Johnson & Johnson Main Business

Table 123. Johnson & Johnson Latest Developments

Table 124. Bristol-Myers Squibb Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors

Table 125. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product Offered

Table 126. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)

Table 127. Bristol-Myers Squibb Main Business

Table 128. Bristol-Myers Squibb Latest Developments

Table 129. Merck Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors

Table 130. Merck Disease-Modifying Antirheumatic Drug Product Offered

Table 131. Merck Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)

Table 132. Merck Main Business

Table 133. Merck Latest Developments

Table 134. UCB S.A. Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors

Table 135. UCB S.A. Disease-Modifying Antirheumatic Drug Product Offered

Table 136. UCB S.A. Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)

Table 137. UCB S.A. Main Business

Table 138. UCB S.A. Latest Developments

Table 139. Eli Lilly and Company Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors

Table 140. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product Offered

Table 141. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)

Table 142. Eli Lilly and Company Main Business

Table 143. Eli Lilly and Company Latest Developments

List of Figures

Figure 1. Picture of Disease-Modifying Antirheumatic Drug

Figure 2. Disease-Modifying Antirheumatic Drug Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Disease-Modifying Antirheumatic Drug Sales Growth Rate 2017-2028 (MT)

Figure 7. Global Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Disease-Modifying Antirheumatic Drug Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Non-Steroidal Anti-Inflammatory Drugs

Figure 10. Product Picture of Steroidal Anti-Inflammatory Drugs

Figure 11. Product Picture of Slow Acting Drug

Figure 12. Product Picture of Immunological Preparation

Figure 13. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2021

Figure 14. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2017-2022)

Figure 15. Disease-Modifying Antirheumatic Drug Consumed in Pharmaceutical Industry

Figure 16. Global Disease-Modifying Antirheumatic Drug Market: Pharmaceutical Industry (2017-2022) & (MT)

Figure 17. Disease-Modifying Antirheumatic Drug Consumed in Hospital and Clinic

Figure 18. Global Disease-Modifying Antirheumatic Drug Market: Hospital and Clinic (2017-2022) & (MT)

Figure 19. Disease-Modifying Antirheumatic Drug Consumed in Other

Figure 20. Global Disease-Modifying Antirheumatic Drug Market: Other (2017-2022) & (MT)

Figure 21. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2022)

Figure 22. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application in 2021

Figure 23. Disease-Modifying Antirheumatic Drug Revenue Market by Company in 2021 ($ Million)

Figure 24. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Company in 2021

Figure 25. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Geographic Region (2017-2022)

Figure 26. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Geographic Region in 2021

Figure 27. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2017-2022)

Figure 28. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Country/Region in 2021

Figure 29. Americas Disease-Modifying Antirheumatic Drug Sales 2017-2022 (MT)

Figure 30. Americas Disease-Modifying Antirheumatic Drug Revenue 2017-2022 ($ Millions)

Figure 31. APAC Disease-Modifying Antirheumatic Drug Sales 2017-2022 (MT)

Figure 32. APAC Disease-Modifying Antirheumatic Drug Revenue 2017-2022 ($ Millions)

Figure 33. Europe Disease-Modifying Antirheumatic Drug Sales 2017-2022 (MT)

Figure 34. Europe Disease-Modifying Antirheumatic Drug Revenue 2017-2022 ($ Millions)

Figure 35. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales 2017-2022 (MT)

Figure 36. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue 2017-2022 ($ Millions)

Figure 37. Americas Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2021

Figure 38. Americas Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2021

Figure 39. United States Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 40. Canada Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 41. Mexico Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 42. Brazil Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 43. APAC Disease-Modifying Antirheumatic Drug Sales Market Share by Region in 2021

Figure 44. APAC Disease-Modifying Antirheumatic Drug Revenue Market Share by Regions in 2021

Figure 45. China Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 46. Japan Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 47. South Korea Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 48. Southeast Asia Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 49. India Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 50. Australia Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 51. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2021

Figure 52. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2021

Figure 53. Germany Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 54. France Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 55. UK Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 56. Italy Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 57. Russia Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 58. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2021

Figure 59. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2021

Figure 60. Egypt Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 61. South Africa Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 62. Israel Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 63. Turkey Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 64. GCC Country Disease-Modifying Antirheumatic Drug Revenue Growth 2017-2022 ($ Millions)

Figure 65. Manufacturing Cost Structure Analysis of Disease-Modifying Antirheumatic Drug in 2021

Figure 66. Manufacturing Process Analysis of Disease-Modifying Antirheumatic Drug

Figure 67. Industry Chain Structure of Disease-Modifying Antirheumatic Drug

Figure 68. Channels of Distribution

Figure 69. Distributors Profiles